Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
Intracerebral hemorrhage (ICH) is a critical disease of public health importance.
Inflammatory mechanisms play a significant role in ICH. Thus, immune targets are supposed to
be effective in protecting the neurological function of ICH. Fingolimod, a
sphingosine-1-phosphate receptor regulator (FTY720), is an effective immunology modulator. It
has been widely used in autoimmune disease and has also been testified effective in ICH who
received conservative treatment. The present study aims to evaluate the efficiency and safety
of fingolimod for ICH with minimal invasive treatment.